

Helen L Reeves

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7352965/helen-l-reeves-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

4,958
citations

28
h-index

70
g-index

83
ext. papers

6,512
ext. citations

7.2
avg, IF

5.37
L-index

#	Paper	IF	Citations
64	Neutrophils as potential therapeutic targets in hepatocellular carcinoma.. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022 ,	24.2	5
63	Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy.. <i>Cell Death and Disease</i> , 2022 , 13, 143	9.8	1
62	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. <i>Nature Cancer</i> , 2022 , 3, 386-401	15.4	8
61	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. <i>Scientific Reports</i> , 2021 , 11, 21286	4.9	0
60	Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. <i>EMBO Journal</i> , 2021 , 40, e106048	13	26
59	A Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021 , 13,	6.6	5
58	NAFLD-Associated HCC: Progress and Opportunities. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 223-239	3.9	11
57	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021 , 12, 555	9.8	2
56	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260.3	0.3	11
55	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
54	High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2021 , 41, 828-836	7.9	4
53	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. <i>Hpb</i> , 2021 , 23, 495-505	3.8	3
52	Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. <i>Hepatobiliary Surgery and Nutrition</i> , 2021 , 10, 59-75	2.1	9
51	Key features of the environment promoting liver cancer in the absence of cirrhosis. <i>Scientific Reports</i> , 2021 , 11, 16727	4.9	4
50	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021 , 7, eabh0534	14.3	1
49	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021 , 75, 865-878	13.4	25
48	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 258-271	15.9	22

47	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020 , 9, 167-181	9.1	16
46	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020 , 73, S13-S14	13.4	3
45	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. <i>Journal of Clinical and Experimental Hepatology</i> , 2020 , 10, 17-29	4.1	5
44	Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1563-1570	2.7	7
43	The CCR2 Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019 , 7, 371-390	7.9	42
42	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019 , 6, 23-30	5.3	9
41	Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population. <i>Hepatic Medicine: Evidence and Research</i> , 2019 , 11, 47-67	3.4	6
40	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 411-428	24.2	425
39	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2018 , 73, 369-385	7.3	26
38	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018 , 118, 248-257	8.7	46
37	Reply to Comment on "Circulating Neutrophils in patients with hepatocellular carcinoma". <i>British Journal of Cancer</i> , 2018 , 119, 781-782	8.7	
36	Liquid biopsy for liver diseases. <i>Gut</i> , 2018 , 67, 2204-2212	19.2	57
35	Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1078-1087	6.7	16
34	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017 , 110, 73-81	2.7	15
33	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
32	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
31	Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2016 , 115, 797-804	8.7	10
30	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2016 , 48, 860-8	3.3	14

29	Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016 , 65, 305-13	13.4	63
28	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1234-45	4	88
27	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. <i>Chemical Science</i> , 2016 , 7, 2821-2826	9.4	4
26	Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver International</i> , 2016 , 36, 911-7.9	12	
25	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016 , 114, 744-50	8.7	119
24	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2016 , 6, 186-194	4.1	8
23	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 875-886.e6	6.9	141
22	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. <i>International Journal of Cancer</i> , 2016 , 138, 206-16	7.5	33
21	Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. <i>Journal of Clinical Oncology</i> , 2015 , 33, 550-8	2.2	1097
20	Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. <i>Journal of Hepatology</i> , 2015 , 62, 1296-303	13.4	72
19	Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases. <i>Organic and Biomolecular Chemistry</i> , 2015 , 13, 5279-84	3.9	9
18	DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. <i>Clinical Cancer Research</i> , 2015 , 21, 925-33	12.9	63
17	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. <i>Journal of Hepatology</i> , 2015 , 62, 982-3	13.4	13
16	Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. <i>Journal of Hepatology</i> , 2014 , 60, 110-7	13.4	367
15	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
14	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area". <i>Journal of Hepatology</i> , 2014 , 60, 1330-1	13.4	1
13	The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 144-53	4	126
12	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. <i>Journal of Hepatology</i> , 2013 , 58, 1000-6	13.4	41

11	Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 1083-93	11.2	50
10	Reply:. <i>Hepatology</i> , 2005 , 41, 682-683	11.2	10
9	Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. <i>Cancer Research</i> , 2005 , 65, 5761-8	10.1	133
8	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. <i>Cancer Research</i> , 2005 , 65, 1213-22	10.1	182
7	Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. <i>Cancer Research</i> , 2004 , 64, 3885-91	10.1	137
6	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004 , 40, 1047-52	11.2	130
5	KLF6, a candidate tumor suppressor gene mutated in prostate cancer. <i>Science</i> , 2001 , 294, 2563-6	33.3	367
4	The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells. <i>Hepatology</i> , 2000 , 31, 95-100	11.2	24
3	Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. <i>Journal of Hepatology</i> , 2000 , 32, 465-72	13.4	65
2	Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. <i>Journal of Hepatology</i> , 1996 , 25, 677-83	13.4	125
1	In Vitro Cytotoxicity of 150 Chemicals to 3T3-L1 Cells, Assessed by the FRAME Kenacid Blue Method. <i>ATLA Alternatives To Laboratory Animals</i> , 1988 , 16, 84-95	2.1	59